ZBH
Zimmer Biomet Holdings, Inc.
NYSEUSDEQUITY
Healthcare
DELAYED
Neutral
-8/100
Last price
89.68
▼ 1.89 (2.06%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
91.57
Day high
91.95
Day low
89.55
Volume
1.68M
Market cap
$17.11B
P/E (TTM)
21.77
52W range
79.12 – 106.88
Trailing performance
Returnvs SPY
1W
-1.82%
-3.8%
1M
-8.56%
-9.7%
3M
+2.42%
-2.1%
6M
-1.88%
-20.1%
YTD
-0.27%
-14.5%
1Y
-11.01%
-27.4%
3Y
-20.09%
-102.3%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on ZBH open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
-148
Net selling
Buy transactions
2
13.54K shares
Sell transactions
3
13.69K shares
Net transactions
+5
Buys less sells
Sell : buy shares
1.0 : 1
Mixed
Insider-held shares
307.09K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Oct 1, 26 | CAMPBELL GARY CRAIG Officer |
— | 3.59K | — | Direct |
| Sep 11, 26 | THORNAL KEVIN R Officer |
SELL | 5.69K | $528.98K | Direct |
| Sep 4, 26 | PHIPPS CHAD F Officer |
SELL | 3.00K | $295.05K | Direct |
| Jul 31, 26 | THORNAL KEVIN R Officer |
— | 9.96K | — | Direct |
| May 29, 26 | YI SANG Officer |
SELL | 5.00K | $413.22K | Direct |
| Apr 1, 26 | NOOR JEHANZEB Officer |
— | 6.63K | — | Direct |
| Mar 12, 26 | WINKLER LORI Officer |
SELL | 2.65K | $250.85K | Direct |
| Mar 6, 26 | PHIPPS CHAD F Officer |
— | 6.79K | — | Direct |
| Mar 6, 26 | UPADHYAY SUKETU P Chief Financial Officer |
— | 14.78K | — | Direct |
| Mar 6, 26 | WINKLER LORI Officer |
— | 5.63K | — | Direct |
| Mar 6, 26 | VAN ZUILEN WILFRED Officer |
— | 7.00K | — | Direct |
| Mar 6, 26 | TORNOS IVAN Chief Executive Officer |
— | 34.70K | — | Direct |
| Mar 6, 26 | YI SANG Officer |
— | 9.41K | — | Direct |
| Mar 6, 26 | STELLATO PAUL A Officer |
— | 1.97K | — | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BEZJAK MARK |
Officer | 13.13K | Conversion of Exercise of derivative security |
ELLINGSON RACHEL H. |
Officer | 11.91K | Conversion of Exercise of derivative security |
NOOR JEHANZEB |
Officer | 5.15K | Conversion of Exercise of derivative security |
PHIPPS CHAD F |
Officer | 65.23K | Sale |
STELLATO PAUL A |
Officer | 5.58K | Conversion of Exercise of derivative security |
TORNOS IVAN |
Chief Executive Officer | 83.19K | Conversion of Exercise of derivative security |
UPADHYAY SUKETU P |
Chief Financial Officer | 69.48K | Conversion of Exercise of derivative security |
VAN ZUILEN WILFRED |
Officer | 30.99K | Conversion of Exercise of derivative security |
WINKLER LORI |
Officer | 10.22K | Sale |
YI SANG |
Officer | 27.25K | Sale |
Fundamentals
Market cap$17.11B
Enterprise value$24.25B
Revenue (TTM)$8.51B
Gross profit$5.92B
EBITDA$2.52B
Net income$806.70M
EPS (TTM)$4.12
Free cash flow$1.07B
Total cash$464.50M
Total debt$7.60B
Book value / share$66.23
Shares outstanding190.74M
Float190.13M
Short % of float5.93%
Dividend yield1.07%
Beta (5Y)0.49
Valuation & profitability ratios
Trailing P/E21.77
Forward P/E9.89
PEG ratio0.58
Price / sales—
Price / book1.35
EV / revenue2.85
EV / EBITDA9.60
Gross margin69.52%
Operating margin17.96%
Profit margin9.48%
Return on equity6.41%
Return on assets3.88%
Debt / equity60.18
Current ratio1.69
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $8.23B | $7.68B | $7.39B | $6.94B | +7.2% |
| Operating revenue | $8.23B | $7.68B | $7.39B | $6.94B | +7.2% |
| Cost of revenue | $2.49B | $2.19B | $2.08B | $2.02B | +13.8% |
| Gross profit | $5.74B | $5.49B | $5.31B | $4.92B | +4.6% |
| Research & development | $458.50M | $437.40M | $458.70M | $406.00M | +4.8% |
| Selling, general & admin | $3.26B | $2.93B | $2.84B | $2.76B | +11.2% |
| Total operating expense | $4.38B | $3.96B | $3.86B | $3.73B | +10.7% |
| Operating income | $1.36B | $1.53B | $1.45B | $1.19B | -11.3% |
| Net interest income | -$292.80M | -$218.00M | -$201.20M | -$164.80M | -34.3% |
| Pre-tax income | $830.80M | $1.04B | $1.07B | $403.50M | -19.9% |
| Tax provision | $125.70M | $131.40M | $42.20M | $112.30M | -4.3% |
| Net income | $705.10M | $903.80M | $1.02B | $231.40M | -22.0% |
| Net income to common | $705.10M | $903.80M | $1.02B | $231.40M | -22.0% |
| Basic EPS | 3.56 | 4.45 | 4.91 | 1.10 | -20.0% |
| Diluted EPS | 3.55 | 4.43 | 4.88 | 1.10 | -19.9% |
| EBIT | $1.12B | $1.25B | $1.27B | $568.30M | -10.4% |
| EBITDA | $2.22B | $2.25B | $2.22B | $1.49B | -1.5% |
| Basic shares | 198.00M | 203.10M | 208.70M | 209.60M | -2.5% |
| Diluted shares | 198.70M | 203.90M | 209.70M | 210.30M | -2.6% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $591.90M | $525.50M | $415.80M | $375.70M | +12.6% |
| Cash & short-term investments | $591.90M | $525.50M | $415.80M | $375.70M | +12.6% |
| Accounts receivable | $1.70B | $1.48B | $1.44B | $1.38B | +15.1% |
| Inventory | $2.29B | $2.24B | $2.39B | $2.15B | +2.3% |
| Total current assets | $5.12B | $4.67B | $4.61B | $4.43B | +9.6% |
| Property, plant & equipment | $2.21B | $2.05B | $2.06B | $1.87B | +7.7% |
| Goodwill & intangibles | $14.66B | $13.55B | $13.67B | $13.64B | +8.2% |
| Total assets | $23.09B | $21.37B | $21.50B | $21.07B | +8.1% |
| Total current liabilities | $2.58B | $2.45B | $2.86B | $2.36B | +5.4% |
| Current debt | $587.10M | $863.00M | $900.00M | $544.30M | -32.0% |
| Long-term debt | $6.93B | $5.34B | $4.87B | $5.15B | +29.8% |
| Total debt | $7.52B | $6.20B | $5.77B | $5.70B | +21.2% |
| Total liabilities | $10.39B | $8.89B | $9.01B | $9.04B | +16.8% |
| Retained earnings | $11.61B | $11.10B | $10.38B | $9.56B | +4.6% |
| Shareholder equity | $12.70B | $12.47B | $12.48B | $12.02B | +1.8% |
| Working capital | $2.54B | $2.22B | $1.75B | $2.07B | +14.2% |
| Net tangible assets | -$1.97B | -$1.08B | -$1.19B | -$1.62B | -81.9% |
| Shares issued | 318.68M | 317.47M | 316.20M | 313.80M | +0.4% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $705.10M | $905.20M | $1.03B | $291.20M | -22.1% |
| Depreciation & amortisation | $1.09B | $996.30M | $951.70M | $926.40M | +9.8% |
| Stock-based compensation | $90.20M | $101.00M | $99.80M | $105.00M | -10.7% |
| Change in working capital | -$104.90M | -$455.40M | -$398.70M | -$311.40M | +77.0% |
| Operating cash flow | $1.70B | $1.50B | $1.58B | $1.28B | +13.2% |
| Capital expenditure | -$276.90M | -$356.80M | -$394.50M | -$217.60M | +22.4% |
| Investing cash flow | -$1.98B | -$888.10M | -$778.90M | -$529.20M | -122.5% |
| Share buybacks | -$487.00M | -$868.00M | -$692.20M | -$126.40M | +43.9% |
| Dividends paid | -$190.30M | -$196.00M | -$200.90M | -$201.20M | +2.9% |
| Financing cash flow | $326.00M | -$484.50M | -$763.50M | -$843.80M | +167.3% |
| Free cash flow | $1.42B | $1.14B | $1.19B | $1.07B | +24.3% |
| End cash position | $591.90M | $525.50M | $415.80M | $375.70M | +12.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $2.18B | $2.09B | $2.24B | $2.00B | $2.08B | — | +4.3% |
| Operating revenue | $1.98B | $2.09B | $2.72B | $1.84B | $1.91B | — | -5.2% |
| Cost of revenue | $635.50M | $576.20M | $792.40M | $559.30M | $592.20M | — | +10.3% |
| Gross profit | $1.54B | $1.51B | $1.45B | $1.44B | $1.49B | — | +2.1% |
| Research & development | $104.80M | $103.40M | $118.70M | $115.90M | $113.30M | — | +1.4% |
| Selling, general & admin | $899.30M | $849.90M | $872.30M | $811.40M | $814.80M | — | +5.8% |
| Total operating expense | $1.17B | $1.12B | $1.17B | $1.10B | $1.09B | — | +4.7% |
| Operating income | $374.00M | $395.10M | $282.60M | $338.30M | $396.40M | — | -5.3% |
| Net interest income | -$72.90M | -$68.80M | -$71.90M | -$75.40M | -$79.30M | — | -6.0% |
| Pre-tax income | $255.10M | $301.30M | $98.00M | $279.20M | $224.60M | — | -15.3% |
| Tax provision | $55.50M | $63.00M | -$39.90M | $48.00M | $71.20M | — | -11.9% |
| Net income | $198.30M | $238.10M | $139.30M | $230.90M | $152.80M | — | -16.7% |
| Net income to common | $198.30M | $238.10M | $139.30M | $230.90M | $152.80M | — | -16.7% |
| Basic EPS | 1.03 | 1.22 | — | 1.17 | 0.77 | 0.92 | -15.6% |
| Diluted EPS | 1.03 | 1.22 | — | 1.16 | 0.77 | 0.91 | -15.6% |
| EBIT | $328.00M | $370.10M | $169.90M | $354.60M | $303.90M | — | -11.4% |
| EBITDA | $598.80M | $640.10M | $453.90M | $638.20M | $575.70M | — | -6.5% |
| Basic shares | 192.20M | 195.00M | — | 198.10M | 197.90M | 198.90M | -1.4% |
| Diluted shares | 192.80M | 195.80M | — | 198.80M | 198.30M | 199.70M | -1.5% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $410.00M | $424.20M | $591.90M | $1.29B | $556.90M | -3.3% |
| Cash & short-term investments | $410.00M | $424.20M | $591.90M | $1.29B | $556.90M | -3.3% |
| Accounts receivable | $1.77B | $1.73B | $1.70B | $1.60B | $1.61B | +2.4% |
| Inventory | $2.27B | $2.25B | $2.29B | $2.48B | $2.45B | +1.0% |
| Total current assets | $5.10B | $4.96B | $5.12B | $5.83B | $5.05B | +2.7% |
| Property, plant & equipment | $2.24B | $2.21B | $2.21B | $2.19B | $2.18B | +1.1% |
| Goodwill & intangibles | $14.38B | $14.48B | $14.66B | $14.44B | $14.60B | -0.7% |
| Total assets | $22.80B | $22.72B | $23.09B | $23.49B | $22.87B | +0.3% |
| Total current liabilities | $3.01B | $2.86B | $2.58B | $2.40B | $2.70B | +5.2% |
| Current debt | $1.20B | $1.18B | $587.10M | $600.00M | $820.00M | +2.2% |
| Long-term debt | $6.28B | $6.30B | $6.93B | $7.51B | $6.75B | -0.3% |
| Total debt | $7.48B | $7.47B | $7.52B | $8.11B | $7.57B | +0.1% |
| Total liabilities | $10.17B | $10.04B | $10.39B | $10.72B | $10.33B | +1.2% |
| Retained earnings | $11.96B | $11.80B | $11.61B | $11.52B | $11.34B | +1.3% |
| Shareholder equity | $12.62B | $12.67B | $12.70B | $12.76B | $12.53B | -0.4% |
| Working capital | $2.08B | $2.10B | $2.54B | $3.43B | $2.35B | -0.7% |
| Net tangible assets | -$1.76B | -$1.81B | -$1.97B | -$1.69B | -$2.08B | +2.7% |
| Shares issued | 190.56M | 319.30M | 318.68M | 318.70M | 318.40M | -40.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | $199.60M | $238.30M | $137.90M | $231.20M | $153.40M | -16.2% |
| Depreciation & amortisation | $270.80M | $270.00M | $284.00M | $283.60M | $271.80M | +0.3% |
| Stock-based compensation | $24.60M | $24.20M | $24.10M | $25.30M | $21.20M | +1.7% |
| Change in working capital | -$47.10M | -$173.30M | $158.60M | -$121.40M | -$68.20M | +72.8% |
| Operating cash flow | $447.80M | $359.40M | $517.40M | $418.70M | $378.20M | +24.6% |
| Capital expenditure | -$116.40M | -$75.30M | -$84.80M | -$65.00M | -$80.10M | -54.6% |
| Investing cash flow | -$190.80M | -$159.00M | -$322.00M | -$163.30M | -$1.38B | -20.0% |
| Share buybacks | -$250.70M | -$250.10M | -$250.00M | $0 | -$7.20M | -0.2% |
| Dividends paid | -$46.50M | -$46.90M | -$47.50M | -$47.50M | -$47.50M | +0.9% |
| Financing cash flow | -$271.10M | -$369.20M | -$897.00M | $483.80M | $163.80M | +26.6% |
| Free cash flow | $331.40M | $284.10M | $432.60M | $353.70M | $298.10M | +16.6% |
| End cash position | $410.00M | $424.20M | $591.90M | $1.29B | $556.90M | -3.3% |
Options analytics
Put / call volume
1.45
Put-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
70.00
-21.9% from spot
ATM implied vol
0.8%
Nearest strike to spot
Skew (10% OTM)
0.0%
Calls bid over puts
Call volume
31
Contracts, this expiry
Put volume
45
Contracts, this expiry
Heaviest call OI
75.00
0 contracts
Heaviest put OI
70.00
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 2.01 | 2.07 | +3.0% |
| Mar 2026 | 1.86 | 2.09 | +12.2% |
| Dec 2025 | 2.40 | 2.42 | +0.9% |
| Sep 2025 | 1.87 | 1.90 | +1.8% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 1.88 | 24 | $2.04B | +1.9% |
| Next quarter | 2.49 | 24 | $2.29B | +2.2% |
| Current year | 8.53 | 27 | $8.60B | +4.4% |
| Next year | 9.07 | 27 | $8.90B | +3.6% |
Analyst targets & ownership
Mean target$107.57
High target$130.00
Low target$93.00
Implied upside19.95%
Analyst count21
ConsensusBUY
Strong buy / Buy3 / 6
Hold18
Sell / Strong sell0 / 0
Held by insiders0.16%
Held by institutions111.39%
Institutions holding1.28K
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
90.10
-0.47% from price
SMA 20
92.56
-3.11% from price
SMA 50
96.04
-6.62% from price
SMA 100
91.93
-2.45% from price
SMA 200
91.33
-1.81% from price
EMA 12
91.01
-1.46% from price
EMA 26
92.95
-3.52% from price
EMA 50
93.71
-4.30% from price
RSI (14)
41.3
Neutral
MACD (12,26,9)
-1.94
Hist -0.26
ATR (14)
2.48
2.77% of price
Realised vol 30D
28.4%
Annualised
Bollinger upper
98.32
20, 2σ
Bollinger lower
86.79
20, 2σ
50 / 200 cross
Golden
96.04 vs 91.33
Trend bias
Below 200
-1.81%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.20
Less volatile than market
Correlation to SPY
0.08
Largely independent
Realised vol 30D
28.4%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-23.5%
Peak to trough
Max drawdown 5Y
-45.7%
Peak to trough
ATR 14
2.48
2.77% of price
Beta (reported)
0.49
5Y monthly, from filing
Short interest
Shares short
8.58M
Prior 8.80M
Change vs prior
-2.5%
Shorts covering
% of float
5.93%
Normal
% of shares out
4.50%
Against total outstanding
Days to cover
5.2
Crowded exit
Float
190.13M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 10, 26 | Canaccord Genuity | MAINTAINED | Hold | Hold |
| Aug 7, 26 | Truist Securities | MAINTAINED | Hold | Hold |
| Aug 6, 26 | RBC Capital | MAINTAINED | Outperform | Outperform |
| Aug 6, 26 | Bernstein | MAINTAINED | Market Perform | Market Perform |
| Aug 6, 26 | Stifel | MAINTAINED | Buy | Buy |
| Jul 9, 26 | BMO Capital | INITIATED | Outperform | Market Perform |
| Jul 6, 26 | Evercore ISI Group | MAINTAINED | Outperform | Outperform |
| May 28, 26 | Citigroup | MAINTAINED | Neutral | Neutral |
| Apr 29, 26 | JP Morgan | MAINTAINED | Neutral | Neutral |
| Apr 29, 26 | Citigroup | MAINTAINED | Neutral | Neutral |
| Apr 29, 26 | Citizens | MAINTAINED | Market Outperform | Market Outperform |
| Apr 29, 26 | Wells Fargo | MAINTAINED | Equal-Weight | Equal-Weight |
Dividends & splits
Forward rate$0.96 / yr
Forward yield1.07%
5-year avg yield0.86%
Payout ratio23.30%
Ex-dividend dateSep 30, 2026
Next pay dateOct 30, 2026
Last split103:100
Split dateMar 1, 2022
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-09-08
Corporate Changes & Voting Matters
8-K · 2026-08-05
Corporate Changes & Voting Matters
8-K · 2026-06-29
Specialized Disclosure Report filed pursuant to Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act relating to the use of conflict minerals (Rule 13p-1)
SD · 2026-05-27
Corporate Changes & Voting Matters
8-K · 2026-05-12
Periodic Financial Reports
10-Q · 2026-05-01
Corporate Changes & Voting Matters
8-K · 2026-04-28
Proxy Statements
DEFA14A · 2026-04-01
Headlines
What Could Lift ISRG Stock?
Trefis · 20h ago
Are Investors Undervaluing Baxter International (BAX) Right Now?
Zacks · 22h ago
Zimmer Biomet Announces Webcast and Conference Call of Third Quarter 2026 Financial Results
PR Newswire · 23h ago
Are You Overpaying For Intuitive Surgical Stock Versus Its Rivals?
Trefis · 5d ago
Do You Really Understand ISRG Stock's Risk?
Trefis · 8d ago
Is ResMed A Better Way Than Stryker To Own Medical Device Growth?
Trefis · 9d ago
Zimmer Biomet (ZBH): Buy, Sell, or Hold Post Q2 Earnings?
StockStory · 11d ago
Zimmer Biomet Holdings (ZBH) Pushes Cost Reset Plans, Is It Still 17% Below Fair Value?
Simply Wall St. · 12d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.